Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Nifty MidSmall Healthcare
Nifty MidSmall Healthcare Performance
Low
₹49,419.35
High
₹50,328.80
52 Week Range
Low
₹40,352.90
High
₹53,415.10
| Previous Close | ₹49,652.40 |
|---|---|
| Day's Range | ₹49,419.35 - ₹50,328.80 |
| Open | ₹49,820.65 |
| 52 Week Range | ₹40,352.90 - ₹53,415.10 |
| Volume | 2,72,33,865 |
Nifty MidSmall Healthcare Companies
| Company Name | LTP (₹) | Change (₹) | Sector |
|---|---|---|---|
| Lupin Ltd. | 1956.50 |  19.60 (1.01%) |
Healthcare |
| Abbott India Ltd. | 26000.00 | 420.00 (1.64%) |
Healthcare |
| Glaxosmithkline Pharmaceuticals Ltd. | 2540.30 | 5.90 (0.23%) |
Healthcare |
| Ipca Laboratories Ltd. | 1915.40 |  -23.00 (-1.19%) |
Healthcare |
| Neuland Laboratories Ltd. | 20890.00 | -125.00 (-0.59%) |
Healthcare |
| Aurobindo Pharma Ltd. | 1693.00 | 48.00 (2.92%) |
Healthcare |
| Natco Pharma Ltd. | 789.40 | -6.00 (-0.75%) |
Healthcare |
| Poly Medicure Ltd. | 1587.10 | -18.10 (-1.13%) |
Healthcare |
| Glenmark Pharmaceuticals Ltd. | 2293.00 | 100.80 (4.60%) |
Healthcare |
| Wockhardt Ltd. | 1996.40 | -33.20 (-1.64%) |
Healthcare |
| Index Name | Market Value | 52W High | 52W Low |
|---|---|---|---|
| Nifty 50 | 22520.45 | 26373.20 | 22179.90 |
| Nifty IT | 28574.9 | 40301.40 | 25699.10 |
| Nifty Next 50 | 68166.7 | 75000.40 | 59896.10 |
| NIFTY50 USD Index | 8068.1 | 10443.40 | 7839.85 |
| Nifty Bank | 55256.65 | 61764.85 | 49954.85 |
| NIFTY Midcap 100 | 58787.3 | 64450.90 | 52032.85 |
| Nifty 500 | 21866.65 | 24144.20 | 20385.65 |
| Nifty Midcap 50 | 16786.7 | 18500.95 | 14804.55 |
| Nifty 100 | 23547.9 | 26975.15 | 22720.45 |
| Nifty FMCG | 44864.25 | 57445.20 | 43442.30 |
Latest News
Aurobindo Pharma informs about newspaper publication
Cohance Lifesciences informs about ESG rating
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, Cohance Lifesciences has informed that Crisil ESG Ratings & Analytics (Crisil ESG Ratings) has voluntarily assigned an ESG Rating of ‘Crisil ESG 61 (Strong)’ and Core ESG Rating of ‘Crisil Core ESG 67 (Strong)’ to the Company. The link for the rating as published by Crisil ESG Ratings: https://www.crisilesg.com/en/home/esg-ratings.html. The Company has not engaged Crisil ESG Ratings for the ESG Rating. The rating has been independently determined by Crisil ESG Ratings based on publicly available information pertaining to the Company.
The above information is a part of company’s filings submitted to BSE.
Lupin informs about press release
Glenmark Pharmaceuticals informs about media release
Aurobindo Pharma informs about acquisition
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The previous close of NFTMIDSMLHEALTH index is ₹50210.25 as of 2026-10-09.
The total volume of NFTMIDSMLHEALTH index is 27214673.00 as of 2026-10-09.
The percentage change in value of NFTMIDSMLHEALTH index is 1.12% as of 2026-10-09.
The absolute increase in NFTMIDSMLHEALTH index value since the previous trading day is ₹557.85 as of 2026-10-09.
A stock reaching its 52-week high indicates it has attained its highest price point in the past year. This milestone may signal strong performance and positive investor sentiment. Please note that investments are subject to market risks.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
